絞り込み

16535

広告

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

著者 Baeten D , Østergaard M , Wei JC , Sieper J , Järvinen P , Tam LS , Salvarani C , Kim TH , Solinger A , Datsenko Y , Pamulapati C , Visvanathan S , Hall DB , Aslanyan S , Scholl P , Padula SJ
Ann Rheum Dis.2018 Jun 26 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (16view , 0users)

Full Text Sources

To evaluate the efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS).
PMID: 29945918 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード